Building trust and loyalty in medical communications – London-based agency reveal their approach
March 17, 2016Medical Communications Synergy Vision, graduate recruitment, medical communications, medical communications agency, recruitment, retention
There has always been a high turnover of staff within the medical communications industry – a recent survey on the …
Grünenthal Group to acquire Almirall’s Mexico unit for about €50 million
March 17, 2016Business Services, Sales and Marketing Almirall, Grünenthal Group, merger and acquisition
Privately-held Grünenthal Group said it has signed a definitive agreement to buy Almirall Group’s Mexico-based business for about €50 million ,to …
FDA approves Bayer haemophilia A drug Kovaltry
March 17, 2016Research and Development, Sales and Marketing Bayer, FDA, approval, drug, drug approval, haemophilia, haemophilia a, kovaltry, viii compound
Bayer (ETR:BAYN) has received approval from the US Food and Drug Administration (FDA) for Kovaltry (octocog alfa), an unmodified, full-length …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
Chugai receive orphan drug status for autoimmune disease treatment
March 17, 2016Manufacturing and Production, Medical Communications, Research and Development chuagi, systemic scleroderma, tocilizumab
Chugai Pharmaceutical Co. (TYO: 4519) has received a notification of orphan drug designation, from the Japanese minister of health, labour …
Baxter to cut stake in Baxalta
March 17, 2016Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter
Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …
Sir Andrew Witty announces decision to step down as CEO of GSK
March 17, 2016Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down
Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …
GSK’s asthma drug meets primary goal in safety study for children
March 17, 2016Research and Development Advair Diskus, GSK, asthma, drug trial
GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
Vectura agree £441m merger with Skyepharma
March 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Skyepharma, UK, biotech, merger, vectura
Vectura (LON: VEC) and Skyepharma (LON: SKP), two UK-based pharma companies, have joined together in a deal worth £441m. The …
Orexigen takes back rights to its weigh management drug from Takeda
March 16, 2016Business Services, Manufacturing and Production, Sales and Marketing Contrave, Orexigen Therapeutics, akeda Pharmaceuticals
Orexigen Therapeutics (Nasdaq: OREX) has taken back the rights to its weight management drug from Japanese pharma giant Takeda Pharmaceuticals …
Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine
March 16, 2016Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech
Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …
GSK establish cell and gene therapy collaboration with Miltenyi Biotec
March 16, 2016Medical Communications, Research and Development GSK, GlaxoSmithKline, cell and gene therapy, collaboration, miltenyi biotec
GlaxoSmithKline (NYSE:GSK) has announced a strategic collaboration with Miltenyi Biotec that will see GSK’s expertise in developing cell and gene …
Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy
March 16, 2016Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development
Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …
New research supports association between Zika virus and microcephaly
March 16, 2016Medical Communications, Research and Development Lancet, Zika virus, french polynesia, microcephaly, outbreak
Using data from the 2013-14 outbreak of Zika virus in French Polynesia, new research in The Lancet has further supported …
PureTech’s Vedanta Biosciences appoints former Genzyme VP chief scientific officer
March 16, 2016Medical Communications, Research and Development Bruce Roberts, Genzyme, Vedanta Biosciences
Vedanta Biosciences, a company developing therapies designed to modulate the human microbiome, has appointed former Genzyme group vice president, Bruce …
Celator’s shares jump on positive late-stage trials for leukaemia drug
March 16, 2016Business Services, Research and Development, Sales and Marketing Celator Pharmaceuticals, EMA, US FDA, Vyxeos, drug trials, phase III
Shares in trial-stage Celator Pharmaceuticals (Nasdaq: CPXX) soared gaining over four times in value as the company announced late-stage trials …
FDA says benefits outweigh risks in Abbott’s heart stent, Absorb
March 16, 2016Research and Development, Sales and Marketing Abbott, absorb, bioresorbable, coronary artery disease
An independent panel convened by the US Food and Drug Administration (FDA) has unanimously voted that the benefits of Absorb, …
Sanofi to use DiCE Molecules’ platform to boost drug discovery
March 16, 2016Research and Development DiCE Molecules, Sanofi
Sanofi has announced a research partnership with newly-launched DiCE Molecules in which the French pharma giant will use DiCE’s small …
Teva says closing buy of Allergan’s generics biz may take longer
March 16, 2016Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva
Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
